GlassScriptPhysician profile
Filippo Cremonini
NPI 1417098567
$35,953.63
in general payments reported to CMS, 2019-2025
32 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $290 · 2021: $18K · 2022: $2,958 · 2023: $522 · 2024: $751 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $17,055.49 | 2021-2023 | |
| Allergan, INC. | $9,718.81 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,057.07 | 2019-2025 | Relistor, Trulance |
| Abbvie INC. | $2,898.96 | 2020-2024 | Rinvoq, Linzess, Skyrizi |
| Janssen Biotech, INC. | $631.81 | 2021-2025 | Stelara, Tremfya, Simponi |
| Ironwood Pharmaceuticals, INC | $367.91 | 2019-2024 | Linzess |
| Genzyme Corporation | $268.71 | 2022-2025 | |
| Gilead Sciences, INC. | $192.63 | 2019-2021 | |
| Braintree Laboratories, INC. | $186.05 | 2019-2023 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $185.03 | 2019-2025 | Entyvio, Eohilia |
| Enterra Medical, INC. | $165.92 | 2024 | |
| Lilly USA, LLC | $155.77 | 2024 | Omvoh |
| Qol Medical, LLC | $129.65 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $111.22 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $94.84 | 2021-2023 | Dificid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $91.27 | 2022 | |
| Phathom Pharmaceuticals, INC. | $88.93 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $87.34 | 2019-2024 | |
| Redhill Biopharma INC. | $81.23 | 2021-2022 | |
| Celgene Corporation | $53.73 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $51.80 | 2023 | Dupixent |
| Olympus America INC. | $51.14 | 2019 | |
| Intra-Sana Laboratories | $50.51 | 2021 | |
| Ardelyx, INC. | $31.71 | 2022 | |
| Celltrion USA INC. | $25.53 | 2024 | Vegzelma |
| Ethicon US, LLC | $22.81 | 2021 | |
| Boston Scientific Corporation | $17.01 | 2019 | |
| Pfizer INC. | $16.52 | 2025 | |
| Novo Nordisk INC | $16.34 | 2025 | Wegovy |
| Capsovision, INC. | $16.06 | 2024 | Capsocam Plus |
| Daiichi Sankyo INC. | $15.97 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Filippo Cremonini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.